Optimizing Sponsor-FDA Interaction During Development
*Duane Snavely, Merck 


We will discuss various opportunities that exist for interaction between statistics/clinical personnel from FDA and industry (e.g., Type A, B or C meetings) and topics that have been important for optimizing drug development and review. Topics include interaction on clinical program and protocol design and analysis issues, impact of emerging external information on ongoing studies, and statistical review aids